Available technologies
Self-assembling, self-adjuvanting system for delivery of peptide-based vaccines
Team
Life Science
Industry
Healthcare
Sector
MedTech Programs
Researchers at the University of Queensland have developed a novel peptide-based immunogenic agent that facilitates self-assembly with peptide epitopes into an immunogenic complex that has adjuvant properties, therefore obviating the need for external adjuvant or other general immune stimulants. The immunogenic agent comprises a peptide covalently coupled or conjugated to one or more peptide epitopes. The compounds produced self-assemble into distinct nanoparticles as well as chain-like aggregates of the nanoparticles under aqueous conditions.
Key features
- Fully defined, peptide-based, self adjuvanting single molecule for the delivery of peptide vaccines without the need for additional adjuvants or other immune stimulants
- Capable of self-assembly into nano/micro particles and are non-toxic and biodegradable
- Capable of inducing strong specific protective immune responses in Group A Streptococcus (GAS) and human papillomavirus (HPV) in mouse models
- Platform technology is adaptable for any peptide-based vaccine.
